Advertisement

February 26, 2019

Robocath's R-One Robotic Device Earns CE Mark Approval to Assist in Coronary Interventions

February 26, 2019—Robocath announced that it has obtained European CE Mark approval of its R-One device for robotic-assisted treatment of coronary artery disease.

According to the company, the R-One robotic device assists interventional cardiologists in angioplasty procedures by enabling precision technologies that complement existing methods, thereby improving procedures and the working environment. R-One's open architecture makes it compatible with market-leading devices and catheterization labs.

With the approval, Robocath is planning to raise financing to support commercialization of the device over the next few years in Europe and the Middle East. Additionally, the company stated that it is finalizing strategic distribution partnerships for an expected launch in 2020.

Advertisement


February 26, 2019

FDA Approval Expands Indication for Medtronic's Resolute DES to Treat De Novo CTO

February 26, 2019

FDA Approval Expands Indication for Medtronic's Resolute DES to Treat De Novo CTO